-

MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at Canaccord Genuity’s 44th Annual Growth Conference:

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following the event.

About MindMed

MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.

Contacts

For Media: media@mindmed.co
For Investors: ir@mindmed.co

Industry:

Mind Medicine Inc.

NASDAQ:MNMD
Release Versions
English
$Cashtags
$MNMD

Contacts

For Media: media@mindmed.co
For Investors: ir@mindmed.co

Social Media Profiles
MindMed LinkedIn
MindMed X
More News From Mind Medicine Inc.

MindMed Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 121,500 common shares of the Company (the "Options"), with an effective grant date of April 21, 2025. The Options have an exercise price...

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Emerge study evaluating MM120 ODT, a proprietary, pharmaceutically optimized form of LSD for the treatment of MDD. Emerge will evaluate the efficacy and safety of MM120 ODT 100 µg versus placebo and is expected...

MindMed Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 88,950 common shares of the Company (the "Options"), with an effective grant date of March 24, 2025. The Options have an exercise price e...
Back to Newsroom